Quantbot Technologies LP Acquires New Holdings in Xeris Biopharma Holdings, Inc. $XERS

Quantbot Technologies LP bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the second quarter, Holdings Channel reports. The fund bought 111,102 shares of the company’s stock, valued at approximately $880,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Landscape Capital Management L.L.C. purchased a new position in shares of Xeris Biopharma during the 2nd quarter valued at $120,000. Ieq Capital LLC purchased a new stake in shares of Xeris Biopharma in the second quarter worth $780,000. Allworth Financial LP bought a new stake in Xeris Biopharma during the second quarter valued at $34,000. BlackRock Inc. bought a new stake in Xeris Biopharma during the second quarter valued at $115,042,000. Finally, Pallas Capital Advisors LLC purchased a new position in Xeris Biopharma during the second quarter worth about $88,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director John Johnson sold 15,000 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $91,350.00. Following the completion of the sale, the director directly owned 683,083 shares in the company, valued at $4,159,975.47. This represents a 2.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the sale, the director directly owned 126,500 shares of the company’s stock, valued at $770,385. The trade was a 11.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 271,499 shares of company stock valued at $2,038,917. Corporate insiders own 4.35% of the company’s stock.

Analyst Upgrades and Downgrades

XERS has been the subject of a number of research analyst reports. Barclays lifted their price target on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $12.00.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $8.68 on Thursday. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The stock has a market cap of $1.58 billion, a PE ratio of -78.91 and a beta of 0.66. The company’s fifty day moving average is $8.22 and its 200 day moving average is $6.90. Xeris Biopharma Holdings, Inc. has a 52 week low of $5.25 and a 52 week high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.